POU4F1, POU class 4 homeobox 1, 5457

N. diseases: 54; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0030354
Disease: Papilloma
Papilloma 		0.030 GeneticVariation disease LHGDN Differential regulation of different human papilloma virus variants by the POU family transcription factor Brn-3a. 16247485 2006
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.020 GeneticVariation group BEFREE Therefore, this study defines the specific interplay between the cellular transactivator Brn-3a, the environmental smoking-related substance nicotine and specific HPV variants in cervical carcinogenesis, and thus helps to explain why some women are susceptible to rapid CIN progression and cancer and others are not. 20190800 2010
CUI: C0302592
Disease: Cervix carcinoma
Cervix carcinoma 		0.020 GeneticVariation disease BEFREE The cellular transcription factor Brn-3a differentially regulates different human papilloma virus (HPV)-16 variants that are associated with different risks of progression to cervical carcinoma in infected humans. 20190800 2010
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.020 GeneticVariation group BEFREE Therefore, this study defines the specific interplay between the cellular transactivator Brn-3a, the environmental smoking-related substance nicotine and specific HPV variants in cervical carcinogenesis, and thus helps to explain why some women are susceptible to rapid CIN progression and cancer and others are not. 20190800 2010
CUI: C0027877
Disease: Neuronal Ceroid-Lipofuscinoses
Neuronal Ceroid-Lipofuscinoses 		0.010 GeneticVariation disease BEFREE The Brn-3a transcription factor gene (POU4F1) maps close to the locus for the variant late infantile form of neuronal ceroid-lipofuscinosis. 8941380 1996
CUI: C0023467
Disease: Leukemia, Myelocytic, Acute
Leukemia, Myelocytic, Acute 		0.320 Biomarker disease CTD_human Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias. 18206229 2008
CUI: C4048328
Disease: cervical cancer
cervical cancer 		0.320 Biomarker disease BEFREE These results indicate that Brn-3a could play an important role in the near future in improving cervical cancer screening. 12911730 2004
CUI: C4048328
Disease: cervical cancer
cervical cancer 		0.320 Biomarker disease CTD_human We observed that BRN3A is independent of the regulative activity of HIPK2 and undergoes positive autoregulation in cervical cancer cells. 21928122 2011
CUI: C0206708
Disease: Cervical Intraepithelial Neoplasia
Cervical Intraepithelial Neoplasia 		0.310 Biomarker disease CTD_human Therefore, this study defines the specific interplay between the cellular transactivator Brn-3a, the environmental smoking-related substance nicotine and specific HPV variants in cervical carcinogenesis, and thus helps to explain why some women are susceptible to rapid CIN progression and cancer and others are not. 20190800 2010
CUI: C0851140
Disease: Carcinoma in situ of uterine cervix
Carcinoma in situ of uterine cervix 		0.310 Biomarker disease CTD_human The cellular transcription factor Brn-3a and the smoking-related substance nicotine interact to regulate the activity of the HPV URR in the cervix. 20190800 2010
CUI: C0007873
Disease: Uterine Cervical Neoplasm
Uterine Cervical Neoplasm 		0.300 Biomarker disease CTD_human Molecular analysis of oncogenicity of the transcription factor, BRN3A, in cervical cancer cells. 21928122 2011
CUI: C0026998
Disease: Acute Myeloid Leukemia, M1
Acute Myeloid Leukemia, M1 		0.300 Biomarker disease CTD_human Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias. 18206229 2008
CUI: C1879321
Disease: Acute Myeloid Leukemia (AML-M2)
Acute Myeloid Leukemia (AML-M2) 		0.300 Biomarker disease CTD_human Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias. 18206229 2008
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.080 Biomarker group BEFREE In tumourigenic melanocytes and fibroblasts, Brn3a accelerated tumour growth in vivo. 23666755 2013
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.080 Biomarker group BEFREE Hence they establish Brn-3a as a key factor in cervical tumorigenesis and as a potential therapeutic target in human cervical neoplasia. 11521202 2001
CUI: C0028840
Disease: Ocular Hypertension
Ocular Hypertension 		0.030 Biomarker disease BEFREE In vivo studies in Adult Dark Agouti (DA) rats with unilateral surgically-induced ocular hypertension (OHT) treated with either CoQ10/TPGS micelles or TPGS vehicle twice daily for three weeks were performed, following which retinal cell health was assessed in vivo using DARC (Detection of Apoptotic Retinal Cells) and post-mortem with Brn3a histological assessment on whole retinal mounts. 28549843 2017
CUI: C0028840
Disease: Ocular Hypertension
Ocular Hypertension 		0.030 Biomarker disease BEFREE Results showed that AOH injury reduced the number of Brn3a-stained retinal ganglion cells (RGCs) and ChAT-amacrine cells; thinned the inner retinal layers and induced apoptosis. 30633922 2019
CUI: C0085648
Disease: Synovial Cyst
Synovial Cyst 		0.030 Biomarker disease BEFREE Cell loss at the ganglion cell layer was assessed with terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL) assay and by evaluating the immunoreactivity of the Brn3a transcription factor. 29853770 2018
CUI: C0085648
Disease: Synovial Cyst
Synovial Cyst 		0.030 Biomarker disease BEFREE The death of RGCs at day 14 was significantly reduced in CAPE‑treated animals compared with the non‑treated group according to Brn3a and TUNEL staining. 31059064 2019
CUI: C0085648
Disease: Synovial Cyst
Synovial Cyst 		0.030 Biomarker disease BEFREE The amount of Brn3a(+) RGC significantly decreased in CS-injected eyes for 10 and 15 (but not 6) weeks. 28498493 2017
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.030 Biomarker phenotype BEFREE Looking for mechanisms linking Brn-3a to carcinogenesis, we discuss the role of this transcription factor in influencing Bcl-2/p53 antagonism and Bcl-2/VEGF induction of tumor angiogenesis, concluding this review with a proposal for the oncogenic nature of Brn-3a. 12405260 2002
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.030 Biomarker phenotype BEFREE This study shows the expression of several trophic peptides and their receptors in benign and malignant pheochromocytomas, and suggests that AM and its RDC1 receptor could be involved in chromaffin cell tumorigenesis through pro-survival effects. 20483910 2010
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.030 Biomarker phenotype BEFREE Hence they establish Brn-3a as a key factor in cervical tumorigenesis and as a potential therapeutic target in human cervical neoplasia. 11521202 2001
CUI: C1258666
Disease: Myxoid cyst
Myxoid cyst 		0.030 Biomarker disease BEFREE Cell loss at the ganglion cell layer was assessed with terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL) assay and by evaluating the immunoreactivity of the Brn3a transcription factor. 29853770 2018
CUI: C1258666
Disease: Myxoid cyst
Myxoid cyst 		0.030 Biomarker disease BEFREE The death of RGCs at day 14 was significantly reduced in CAPE‑treated animals compared with the non‑treated group according to Brn3a and TUNEL staining. 31059064 2019